First Horizon Advisors’s NovoCure NVCR Stock Holding History

First Horizon Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-244	Closed	-$17.9K	–	2519
2022 Q4	$17.9K	Hold	244	–	–	﹤0.01%	1291
2022 Q3	$17K	Sell	244 -3	-1%	-$234	﹤0.01%	1301
2022 Q2	$16K	Buy	+247	New	+$18.6K	﹤0.01%	1379
2022 Q1	–	Sell	-271	Closed	-$19K	–	2108
2021 Q4	$19K	Buy	271 +9	+3%	+$903	﹤0.01%	1300
2021 Q3	$30K	Buy	262 +10	+4%	+$1.51K	﹤0.01%	1121
2021 Q2	$54K	Sell	252 -40	-14%	-$7.78K	﹤0.01%	755
2021 Q1	$38K	Sell	292 -27	-8%	-$4.27K	﹤0.01%	845
2020 Q4	$55K	Buy	319 +27	+9%	+$3.69K	﹤0.01%	570
2020 Q3	$32K	Sell	292 -143	-33%	-$11.4K	﹤0.01%	671
2020 Q2	$26K	Hold	435	–	–	﹤0.01%	711
2020 Q1	$28K	Buy	435 +303	+230%	+$23.9K	﹤0.01%	619
2019 Q4	$11K	Buy	+132	New	+$10.7K	﹤0.01%	1046

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

First Horizon Advisors's NVCR Position: Q1 2023 in Review

First Horizon Advisors sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 244 shares — an estimated $17.9K sold.

First Horizon Advisors first reported a position in NVCR in Q4 2019 and held it in 12 quarters. The position peaked at $55K in Q4 2020. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

First Horizon Advisors reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
First Horizon Advisors sold 244 NovoCure shares in Q1 2023, an estimated $17.9K.
First Horizon Advisors first reported a position in NovoCure in Q4 2019 and held it in 12 quarters.
First Horizon Advisors's NovoCure position peaked at $55K in Q4 2020.
295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on First Horizon Advisors's 13F filing for Q1 2023, filed 15 May 2023.